New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
Official Eli Lilly and Company company announcement. Read the original release for details. This concerns the underlying company, not the issuer of wLLY.
- Evidence role
- Underlying company Eli Lilly Investor Relations
- Temporal state
- Dated publication The source supplied a parseable publication timestamp.
- Identity scope
- One exact market wLLY mapped by registered currency and issuer identity.
- Evidence network
- 13 related records 11 from this source channel
wLLY
XRPL token market
What this record establishes
Eli Lilly and Company published the announcement “New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity”.
Coverage context
This update concerns Eli Lilly and Company. Trensik maps the coverage to the related XRPL asset for market context only; the company is not represented as the token issuer.
Underlying or reference-market context
Official Eli Lilly and Company company announcement. Read the original release for details. This concerns the underlying company, not the issuer of wLLY.
Exact XRPL token context
wLLY is independently issued on XRPL. News relevance does not establish price parity, liquidity, ownership, sponsorship, or endorsement. The token chart reports only the exact registered XRPL market.
Source and verification
The date and article link come from Eli Lilly Investor Relations. The original publisher is the source of the full announcement.
Market charts are informational and may update on a different schedule from the source article.
Related coverage
wLLYFDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
Official Eli Lilly and Company company announcement. Read the original release for details. This concerns the underlying company, not the issuer of wLLY.
FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
Official Eli Lilly and Company company announcement. Read the original release for details. This concerns the underlying company, not the issuer of wLLY.
La FDA aprueba Mounjaro (tirzepatida) de Lilly para reducir el riesgo cardiovascular en adultos con diabetes tipo 2
Official Eli Lilly and Company company announcement. Read the original release for details. This concerns the underlying company, not the issuer of wLLY.
Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020
Official Eli Lilly and Company company announcement. Read the original release for details. This concerns the underlying company, not the issuer of wLLY.
Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
Official Eli Lilly and Company company announcement. Read the original release for details. This concerns the underlying company, not the issuer of wLLY.
